Treating the lesions, not the disease

American Journal of Pathology

Volumn 170, Issue 5, 2007, Pages 1457-1459

  Zhu, Xiongwei ^a   Avila, Jesus ^b   Perry, George ^a,c   Smith, Mark A ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^c University of San Antonio   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; LITHIUM; TAU PROTEIN; LITHIUM DERIVATIVE;

ALZHEIMER DISEASE; DRUG MECHANISM; HUMAN; NERVE DEGENERATION; NEUROPATHOLOGY; NONHUMAN; NOTE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; ANIMAL; BRAIN; DRUG EFFECT; MOUSE; PATHOLOGY; SENILE PLAQUE; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; BRAIN; HUMANS; LITHIUM COMPOUNDS; MICE; MICE, TRANSGENIC; SENILE PLAQUES; TAU PROTEINS;

EID: 34250796278     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.2353/ajpath.2007.070193     Document Type: Note

References (27)

1. Caccamo A, Oddo S, Tran LX, LaFerla FM: Lithium reduces tau phosphorylation but not Abeta or working memory deficits in a transgenic model with both plaques and tangles. Am J Pathol 2007, 170:1669-1675
2. Oddo S, Caccamo A, Tran L, Lambert MP, Glabe CG, Klein WL, LaFerla FM: Temporal profile of amyloid-beta (Abeta) oligomerization in an in vivo model of Alzheimer disease. A link between Abeta and tau pathology. J Biol Chem 2006, 281:1599-1604
3. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L: The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991, 41:479-486
4. Castellani RJ, Lee HG, Zhu X, Nunomura A, Perry G, Smith MA: Neuropathology of Alzheimer disease: pathognomonic but not pathogenic. Acta Neuropathol (Berl) 2006, 111:503-509
5. Perry G, Raina AK, Cohen ML, Smith MA: When hypotheses dominate. The Scientist 2004, 18:6
6. Mattson MP, Tomaselli KJ, Rydel RE: Calcium-destabilizing and neurodegenerative effects of aggregated beta-amyloid peptide are attenuated by basic FGF. Brain Res 1993, 621:35-49
7. Rogaev EI, Sherrington R, Rogaeva EA, Levesque G, Ikeda M, Liang Y, Chi H, Lin C, Holman K, Tsuda T, Mar L, Sorbi S, Nacmias B, Piacentini S, Amaducci L, Chumakov I, Cohen D, Lannfelt L, Fraser PE, Rommens JM, St George-Hyslop PH: Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature 1995, 376:775-778
8. Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, Fidani L, Giuffra L, Haynes A, Irving N, James L, Mant R, Newton P, Rooke K, Roques P, Talbot C, Pericak-Vance M, Roses A, Williamson R, Rossor M, Owen M, Hardy J: Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 1991, 349:704-706
9. Hardy JA, Higgins GA: Alzheimer's disease: the amyloid cascade hypothesis. Science 1992, 256:184-185
10. Hardy J, Selkoe DJ: The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356
11. Takeuchi A, Irizarry MC, Duff K, Saido TC, Hsiao Ashe K, Hasegawa M, Mann DM, Hyman BT, Iwatsubo T: Age-related amyloid beta deposition in transgenic mice overexpressing both Alzheimer mutant presenilin 1 and amyloid beta precursor protein Swedish mutant is not associated with global neuronal loss. Am J Pathol 2000, 157:331-339
12. Irizarry MC, McNamara M, Fedorchak K, Hsiao K, Hyman BT: APPSw transgenic mice develop age-related A beta deposits and neuropil abnormalities, but no neuronal loss in CA1. J Neuropathol Exp Neurol 1997, 56:965-973
13. Irizarry MC, Soriano F, McNamara M, Page KJ, Schenk D, Games D, Hyman BT: Abeta deposition is associated with neuropil changes, but not with overt neuronal loss in the human amyloid precursor protein V717F (PDAPP) transgenic mouse. J Neurosci 1997, 17:7053-7059
14. Joseph J, Shukitt-Hale B, Denisova NA, Martin A, Perry G, Smith MA: Copernicus revisited: amyloid beta in Alzheimer's disease. Neurobiol Aging 2001, 22:131-146
15. D'Souza I, Poorkaj P, Hong M, Nochlin D, Lee VM, Bird TD, Schellenberg GD: Missense and silent tau gene mutations cause frontotemporal dementia with parkinsonism-chromosome 17 type, by affecting multiple alternative RNA splicing regulatory elements. Proc Natl Acad Sci USA 1999, 96:5598-5603
16. Yamaguchi H, Ishiguro K, Uchida T, Takashima A, Lemere CA, Imahori K: Preferential labeling of Alzheimer neurofibrillary tangles with antisera for tau protein kinase (TPK) I/glycogen synthase kinase-3 beta and cyclin-dependent kinase 5, a component of TPK II. Acta Neuropathol (Berl) 1996, 92:232-241
17. Leroy K, Yilmaz Z, Brion JP: Increased level of active GSK-3beta in Alzheimer's disease and accumulation in argyrophilic grains and in neurones at different stages of neurofibrillary degeneration. Neuropathol Appl Neurobiol 2007, 33:43-55
18. Nunomura A, Perry G, Aliev G, Hirai K, Takeda A, Balraj EK, Jones PK, Ghanbari H, Wataya T, Shimohama S, Chiba S, Atwood CS, Petersen RB, Smith MA: Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol 2001, 60:759-767
19. Nunomura A, Perry G, Pappolla MA, Wade R, Hirai K, Chiba S, Smith MA: RNA oxidation is a prominent feature of vulnerable neurons in Alzheimer's disease. J Neurosci 1999, 19:1959-1964
20. Lee KY, Koh SH, Noh MY, Park KW, Lee YJ, Kim SH: Glycogen synthase kinase-3beta activity plays very important roles in determining the fate of oxidative stress-inflicted neuronal cells. Brain Res 2007, 1129:89-99
21. Götz J, Chen F, Barmettler R, Nitsch RM: Tau filament formation in transgenic mice expressing P301L tau. J Biol Chem 2001, 276:529-534
22. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFerla FM: Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 2003, 39:409-421
23. Wada A, Yokoo H, Yanagita T, Kobayashi H: Lithium: potential therapeutics against acute brain injuries and chronic neurodegenerative diseases. J Pharmacol Sci 2005, 99:307-321
24. Engel T, Goni-Oliver P, Lucas JJ, Avila J, Hernandez F: Chronic lithium administration to FTDP-17 tau and GSK-3beta overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert. J Neurochem 2006, 99:1445-1455
25. Engel T, Hernandez F, Avila J, Lucas JJ: Full reversal of Alzheimer's disease-like phenotype in a mouse model with conditional overexpression of glycogen synthase kinase-3. J Neurosci 2006, 26:5083-5090
26. Perry G, Nunomura A, Raina AK, Smith MA: Amyloid-beta junkies. Lancet 2000, 355:757
27. Smith MA, Atwood CS, Joseph JA, Perry G: Predicting the failure of amyloid-beta vaccine. Lancet 2002, 359:1864-1865